WDGMC
5.4.2022 08:47:12 CEST | Business Wire | Press release
Wits University Donald Gordon Medical Centre announced novel study results indicating for the first time that Ultraviolet (UV) room decontamination technology paired with manual cleaning protocols decreased the transmission of Carbapenem-resistant Enterobacterales (CRE) by 23% in a hospital setting. The study results have been published in the March 2022 issue of The Journal of Hospital Infection.
The team of researchers at Wits Donald Gordon Medical Centre (WDGMC), the first private teaching hospital in South Africa, demonstrated the reduction in CRE transmission following a 26-month study and the sustained use of a UV room decontamination device (UVDI-360 Room Sanitizer, provided by US-based manufacturer UVDI and eHealthGroup Infection Control) as an adjunct to standard cleaning, including the use of bleach and quaternary ammonium disinfectants, across the 210-bed hospital. The intervention included broad UV room decontamination across five high-risk patient units (including critical care, oncology, transplant and gastrointestinal surgery rooms) during a 12-month period following a 12-month baseline and two-month, wash-in period.
“Our team’s study indicated that enhanced environmental hygiene utilizing UV room decontamination technology in the hospital can help prevent the transmission of Carbapenem-resistant Enterobacterales , an especially challenging set of multidrug-resistant organisms,” stated lead investigator Dr. Warren Lowman, Clinical Microbiologist & Infection Prevention and Control Specialist, Wits Donald Gordon Medical Centre.
The UV room decontamination device was implemented in three usage scenarios: terminal cleaning following patient discharge, terminal cleaning following patient transfer and, in a novel treatment, occupied rooms where the patient had an existing MDRO infection and was moved during device use. For each scenario, the UV device was operated with five-minute treatment cycles, the number of which varied per room setting and size.
CRE refers to a broader set of microorganisms that demonstrate resistance to at least one of the Carbapenem antibiotics.1 Recent published surveillance studies in South Africa have indicated a CRE infection crude mortality rate of nearly 40%.2
“This research underlines WDGMC’s steadfast commitment to patient and staff safety through the use of novel infection prevention protocols,” said Dr. Sue Tager, Chief Executive Officer, Wits Donald Gordon Medical Centre. “In the ongoing fight to prevent the transmission of superbugs, both in and beyond Africa, these results provide hope and concrete proof that effective solutions exist.”
About Wits Donald Gordon Medical Centre
Wits Donald Gordon Medical Centre (WDGMC) is the first and only private teaching hospital in South Africa. It was established in 2002 when the University of the Witwatersrand (Wits University) bought the Kenridge Hospital with a founding donation from the Donald Gordon Foundation. The institution was then renamed the Wits Donald Gordon Medical Centre. The 210-bed facility’s main specialties are transplant surgery, oncology (paediatric and adult), gastroenterology (medical and surgical), geriatric medicine, interventional radiology ophthalmology, ear-nose and throat, urology, nephrology, cardiology, women’s health and orthopaedics.
___________
1
https://www.cdc.gov/hai/organisms/cre/technical-info.html
2
Perovic O, Ismail H, Quan V, Bamford C, Nana T, Chibabhai V, Bhola P, Ramjathan P, Swe Swe-Han K, Wadula J, Whitelaw A, Smith M, Mbelle N, Singh-Moodley A; for GERMS-SA. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1287-1294. doi: 10.1007/s10096-020-03845-4. Epub 2020 Mar 2. PMID: 32124106.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404006042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom